Only China locations: A Study of APS03118 in Adult Patients With Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions

Inclusion criteria: Have histological or cytological confirmation of unresectable locally advanced or metastatic solid tumors harboring oncogenic RET mutations or fusions.

Sponsor/Collaborator: Applied Pharmaceutical Science, Inc.

Contact and Locations:
Study Contact: Jun Zhong, PhD
Phone Number: +86 13820403158
China, Shanghai. Shanghai Chest Hospital
Shanghai, Shanghai, China, 200030
Contact: Shun Lu, MD, PhD

Mechanism of action: APS03118 is a novel next-generation RET inhibitor which is potent against a range of RET fusions and mutations including both solvent front and gatekeeper resistance mutations.

Phases: Phase 1

NCT Number: NCT05653869

Status: Recruiting

Back to clinical trials list